
ECCO 2019

Read the full Report (pdf)
European Crohn's and Colitis Organisation
6–9 March 2019, Copenhagen, Denmark
Featured articles


Interview with Prof. Janneke van der Woude
CONTENTS
Online First
New Compounds: Study Results
Selective oral sphingosine 1-phosphate receptor modulator amiselimod
Selective sphingosine-1-phosphate receptor modulator etrasimod

OPERA II study: MAdCAM-1 antibody SHP647

Upadacitinib: data from U-ACHIEVE and CELEST

Cyclosporine: novel low-dose, controlled-release formulation
Short-term and Long-term Treatment Results
The right drug for the right patient
Vedolizumab superior to adalimumab in ulcerative colitis
Vedolizumab: Results from the GEMINI programme

Ustekinumab as maintenance therapy and with shortened interval
Tofacitinib: Results from the OCTAVE open-label studies
Safety of thiopurine + allopurinol vs thiopurine monotherapy
Limited long-term effectiveness and safety of tacrolimus in ulcerative colitis
Complementary and Alternative Medicine
Topical review
Complementary and alternative medicine associated with chronic fatigue and lower QoL
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease

Microbial composition and psychological wellbeing
Glycans as novel immunomodulators in inflammatory bowel disease
Remission

Early remission of Crohn’s disease prevents progression
Histological remission predicts relapse-free survival in ulcerative colitis
Proactive adalimumab trough measurements
Observational Studies

The costs and benefits of biologicals
Efficacy and safety of biosimilars
IBD risk of treatment with IL-17 antagonists
Basic and Preclinical Research
Pathogenesis
